Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAJDA1614

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	JUL 02	LMEDLINE coverage updated
NEWS 3	JUL 02	SCISEARCH enhanced with complete author names
NEWS 4	JUL 02	CHEMCATS accession numbers revised
NEWS 5	JUL 02	CA/CAplus enhanced with utility model patents from China
NEWS 6	JUL 16	CAplus enhanced with French and German abstracts
NEWS 7	JUL 18	CA/CAplus patent coverage enhanced
NEWS 8	JUL 26	USPATFULL/USPAT2 enhanced with IPC reclassification
NEWS 9	JUL 30	USGENE now available on STN
NEWS 10	AUG 06	CAS REGISTRY enhanced with new experimental property tags
NEWS 11	AUG 06	FSTA enhanced with new thesaurus edition
NEWS 12	AUG 13	CA/CAplus enhanced with additional kind codes for granted patents
NEWS 13	AUG 20	CA/CAplus enhanced with CAS indexing in pre-1907 records
NEWS 14	AUG 27	Full-text patent databases enhanced with predefined patent family display formats from INPADOCDB
NEWS 15	AUG 27	USPATOLD now available on STN
NEWS 16	AUG 28	CAS REGISTRY enhanced with additional experimental spectral property data
NEWS 17	SEP 07	STN AnaVist, Version 2.0, now available with Derwent World Patents Index
NEWS 18	SEP 13	FORIS renamed to SOFIS
NEWS 19	SEP 13	INPADOCDB enhanced with monthly SDI frequency
NEWS 20	SEP 17	CA/CAplus enhanced with printed CA page images from 1967-1998
NEWS 21	SEP 17	CAplus coverage extended to include traditional medicine patents
NEWS 22	SEP 24	EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS 23	OCT 02	CA/CAplus enhanced with pre-1907 records from Chemisches Zentralblatt
NEWS 24	OCT 19	BEILSTEIN updated with new compounds

NEWS EXPRESS 19 SEPTEMBER 2007: CURRENT WINDOWS VERSION IS V8.2, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 19 SEPTEMBER 2007.

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 10:55:13 ON 13 NOV 2007

=> file registry

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 10:55:24 ON 13 NOV 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 12 NOV 2007 HIGHEST RN 953132-99-5
DICTIONARY FILE UPDATES: 12 NOV 2007 HIGHEST RN 953132-99-5

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10830147_specie.str



```
chain nodes :
10  12  19  20  21  23  29  30  36  37  38  39  40
ring nodes :
1  2  3  4  5  6  7  8  9  11  13  14  15  16  17  18  22  24  25  26  27  28  31
32  33  34  35
chain bonds :
2-37  7-10  8-36  10-11  10-12  12-13  16-19  19-20  19-30  20-21  20-23  21-22
26-29  37-38  37-40  38-39
ring bonds :
1-2  1-6  2-3  3-4  4-5  5-6  5-7  6-9  7-8  8-9  11-31  11-35  13-14  13-18  14-15
 15-16  16-17  17-18  22-24  22-28  24-25  25-26  26-27  27-28  31-32  32-33  33-34
 34-35
exact/norm bonds :
5-7  6-9  7-8  8-9  8-36  10-12  12-13  16-19  19-20  20-23  22-24  22-28  24-25
25-26  26-27  27-28  37-38  37-40
exact bonds :
2-37  7-10  10-11  19-30  20-21  21-22  26-29  38-39
normalized bonds :
1-2  1-6  2-3  3-4  4-5  5-6  11-31  11-35  13-14  13-18  14-15  15-16  16-17
17-18  31-32  32-33  33-34  34-35


Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:Atom  8:Atom  9:Atom  10:CLASS
11:Atom  12:CLASS  13:Atom  14:Atom  15:Atom  16:Atom  17:Atom  18:Atom  19:CLASS
20:CLASS  21:CLASS  22:Atom  23:CLASS  24:Atom  25:Atom  26:Atom  27:Atom  28:Atom
29:CLASS  30:CLASS  31:Atom  32:Atom  33:Atom  34:Atom  35:Atom  36:CLASS  37:CLASS
 38:CLASS  39:CLASS  40:CLASS



L1      STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1              STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY -  AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.


=> s l1 full
FULL SEARCH INITIATED 10:55:45 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -     1349 TO ITERATE

100.0% PROCESSED     1349 ITERATIONS                                  6 ANSWERS
SEARCH TIME: 00.00.01

L2            6 SEA SSS FUL L1

=> file medline caplus wpids uspatfull
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                   172.10     172.31

FILE 'MEDLINE' ENTERED AT 10:55:57 ON 13 NOV 2007

FILE 'CAPLUS' ENTERED AT 10:55:57 ON 13 NOV 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'WPIDS' ENTERED AT 10:55:57 ON 13 NOV 2007
```

COPYRIGHT (C) 2007 THE THOMSON CORPORATION

FILE 'USPATFULL' ENTERED AT 10:55:57 ON 13 NOV 2007
CA INDEXING COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

=> s l2
SAMPLE SEARCH INITIATED 10:56:02 FILE 'WPIDS'
SAMPLE SCREEN SEARCH COMPLETED - 2 TO ITERATE

100.0% PROCESSED 2 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 2 TO 62
PROJECTED ANSWERS: 0 TO 0

L3 17 L2

=>
=> s l3 and cancer
L4 7 L3 AND CANCER

=> d l4 1-7 ibib, abs, hitstr

L4 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2007:563428 CAPLUS
DOCUMENT NUMBER: 146:514733
TITLE: Treatment of cancer with indolinones
INVENTOR(S): Sommergruber, Wolfgang; Kraut, Norbert; Schweifer, Norbert; Rettig, Wolfgang; Hilberg, Frank; Solca, Flavio; Steegmaier, Martin
PATENT ASSIGNEE(S): Boehringer Ingelheim International GmbH, Germany; Boehringer Ingelheim Pharma Gmbh & Co. KG
SOURCE: PCT Int. Appl., 47pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007057397	A1	20070524	WO 2006-EP68459	20061114

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: EP 2005-110777 A 20051115
OTHER SOURCE(S): MARPAT 146:514733
AB The invention is based on the finding that indolinones are useful for the therapy of diseases which result from aberrant activity of certain tyrosine kinases selected from the group comprising ABL, FGFR3, FLT3, and RET.
IT 656247-18-6
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(treatment of cancer with indolinone derivs.)

RN 656247-18-6 CAPLUS

CN 1H-Indole-6-carboxylic acid, 2,3-dihydro-3-[[[4-[methyl[2-(4-methyl-1-piperazinyl)acetyl]amino]phenyl]amino]phenylmethylene]-2-oxo-, methyl ester, (3Z)-, ethanesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 656247-17-5
CMF C31 H33 N5 O4

Double bond geometry as shown.



CM 2

CRN 594-45-6
CMF C2 H6 O3 S



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2007:537782 CAPLUS
DOCUMENT NUMBER: 146:514717
TITLE: Combination treatment of cancer comprising EGFR/HER2 inhibitors
INVENTOR(S): Solca, Flavio; Amelsberg, Andree; Stehle, Gerd; Van Meel, Jacobus C. A.; Baum, Anke
PATENT ASSIGNEE(S): Boehringer Ingelheim International GmbH, Germany; Boehringer Ingelheim Pharma GmbH & Co. KG
SOURCE: PCT Int. Appl., 107pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007054551	A1	20070518	WO 2006-EP68314	20061109

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,

GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN,
KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK,
MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO,
RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT,
TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: EP 2005-110669 A 20051111
OTHER SOURCE(S): MARPAT 146:514717

GI



I

AB The invention discloses a therapy of cancer comprising co-administration to a person in need of such treatment and/or co-treatment of a person in need of such treatment with effective amts. of (1) a compound I (Ra = benzyl, 1-phenylethyl, 3-chloro-4-fluorophenyl; Rb = H, C1-4 alkyl; Rc = cyclopropylmethoxy, cyclobutoxy, etc.; Rd = dimethylamino, N-cyclopropyl-N-methylamino, etc.); and (2) at least a further chemotherapeutic agent; optionally in combination with radiotherapy, radioimmunotherapy and/or tumor resection by surgery. The invention further discloses corresponding medicaments and the preparation thereof.

IT 656247-17-5 656247-17-5D, salts and metabolites
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(EGFR/HER2 inhibitor combination treatment for cancer)

RN 656247-17-5 CAPLUS

CN 1H-Indole-6-carboxylic acid, 2,3-dihydro-3-[[[4-[methyl[2-(4-methyl-1-piperazinyl)acetyl]amino]phenyl]amino]phenylmethylene]-2-oxo-, methyl ester, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.



RN 656247-17-5 CAPLUS

CN 1H-Indole-6-carboxylic acid, 2,3-dihydro-3-[[[4-[methyl[2-(4-methyl-1-piperazinyl)acetyl]amino]phenyl]amino]phenylmethylene]-2-oxo-, methyl ester, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:167588 CAPLUS
DOCUMENT NUMBER: 144:254148
TITLE: Aminopteridinones as anticancer agents, their preparation, pharmaceutical compositions, and use in therapy
INVENTOR(S): Munzert, Gerd; Steegmaier, Martin; Baum, Anke
PATENT ASSIGNEE(S): Boehringer Ingelheim International G.m.b.H., Germany; Boehringer Ingelheim Pharma G.m.b.H. & Co. K.-G.
SOURCE: PCT Int. Appl., 158 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006018182	A1	20060223	WO 2005-EP8623	20050809
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
US 2006058311	A1	20060316	US 2005-189540	20050726
AU 2005274384	A1	20060223	AU 2005-274384	20050809
CA 2576269	A1	20060223	CA 2005-2576269	20050809
EP 1827441	A1	20070905	EP 2005-770228	20050809
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BA, HR, YU				
CN 101039673	A	20070919	CN 2005-80035272	20050809
IN 2007DN00888	A	20070803	IN 2007-DN888	20070202
KR 2007050478	A	20070515	KR 2007-705955	20070314

PRIORITY APPLN. INFO.:	EP 2004-19361	A	20040814
	EP 2004-19448	A	20040817
	WO 2005-EP8623	W	20050809

OTHER SOURCE(S): MARPAT 144:254148
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention relates to a group of aminopteridinones I, which are useful for the treatment of diseases which involve cell proliferation. In compds. I, R1 and R2 are independently selected from H and (un)substituted C1-6 alkyl, or R1 and R2 together form a 2- to 5-membered alkylene bridge, optionally containing 1 or 2 heteroatoms; R3 is (un)substituted C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C6-14 aryl, etc.; R4 is H, OH, CN, halo, (un)substituted amino, (un)substituted C1-6 alkyl, C1-5 alkoxy, etc.; L is (un)substituted C2-10 alkylene, (un)substituted C2-10 alkenylene, (un)substituted C6-14 arylene, etc.; R5 is (un)substituted morpholinyl, (un)substituted piperidinyl, (un)substituted piperazinyl, (un)substituted piperazinylcarbonyl, (un)substituted pyrrolidinyl, (un)substituted thiomorpholinyl, etc.; n is 0 or 1; and m is 1 or 2; including tautomers, stereoisomers, salts, solvates, polymorphs, and prodrugs thereof. The invention also relates to the preparation of I, pharmaceutical compns. comprising a compound I, at least one other therapeutic agent, optionally with one or more pharmaceutically acceptable excipients, as well as to the use of the compns. for the treatment of diseases which involve cell proliferation, migration or apoptosis of cancer cells, or angiogenesis. Esterification of (R)-2-aminobutyric acid and reductive condensation with cyclopentanone gave cyclopentylamine II, which underwent regioselective substitution of 2,4-dichloro-5-nitropyrimidine and reductive heterocyclization to form pteridinone III. N-Methylation of III followed by substitution with 4-amino-3-methoxybenzoic acid and amidation with 1-methyl-4-aminopiperidine resulted in the formation of aminopteridinone IV. A combination of suboptimal doses of irinotecan and compound IV shows an additive/synergistic effect in a human colon carcinoma model and is well tolerated. Meanwhile, compound IV acts at least additively with docetaxel in a human non-small cell lung carcinoma model and not antagonistically with gemcitabine in a human adenocarcinoma model.

IT 656247-17-5
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(preparation of aminopteridinones for use in combination therapy for treatment of cell proliferative diseases)

RN 656247-17-5 CAPLUS

CN 1H-Indole-6-carboxylic acid, 2,3-dihydro-3-[[[4-[methyl[2-(4-methyl-1-piperazinyl)acetyl]amino]phenyl]amino]phenylmethylene]-2-oxo-, methyl ester, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 7 USPATFULL on STN

ACCESSION NUMBER: 2006:167862 USPATFULL
TITLE: Medicaments for the Treatment or Prevention of Fibrotic Diseases
INVENTOR(S): Park, John Edward, Biberach, GERMANY, FEDERAL REPUBLIC OF
Roth, Gerald Juergen, Biberach, GERMANY, FEDERAL REPUBLIC OF
Heckel, Armin, Biberach, GERMANY, FEDERAL REPUBLIC OF
Chaudhary, Nveed, Biberach, GERMANY, FEDERAL REPUBLIC OF
Brandl, Trixi, Warthausen, GERMANY, FEDERAL REPUBLIC OF
Dahmann, Georg, Attenweiler, GERMANY, FEDERAL REPUBLIC OF
Grauert, Matthias, Biberach, GERMANY, FEDERAL REPUBLIC OF
PATENT ASSIGNEE(S): Boehringer Ingelheim International GmbH, Ingelheim, GERMANY, FEDERAL REPUBLIC OF (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2006142373	A1	20060629
APPLICATION INFO.:	US 2005-275223	A1	20051220 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	EP 2004-30770	20041224

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: MICHAEL P. MORRIS, BOEHRINGER INGELHEIM CORPORATION, 900 RIDGEBURY ROAD, P. O. BOX 368, RIDGEFIELD, CT, 06877-0368, US
NUMBER OF CLAIMS: 9
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 6 Drawing Page(s)
LINE COUNT: 4993
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to the use of indolinones of general formula ##STR1## substituted in the 6 position, wherein R.sub.1 to R.sub.5 and X are defined as in claim 1, the isomers and the salts thereof, particularly the physiologically acceptable salts thereof, as a medicament for the prevention or treatment of specific fibrotic diseases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 656247-17-5 656247-18-6
(indolinones for treatment of fibrotic diseases)
RN 656247-17-5 USPATFULL
CN 1H-Indole-6-carboxylic acid, 2,3-dihydro-3-[[[4-[methyl[2-(4-methyl-1-piperazinyl)acetyl]amino]phenyl]amino]phenylmethylene]-2-oxo-, methyl ester, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.



RN 656247-18-6 USPATFULL
CN 1H-Indole-6-carboxylic acid, 2,3-dihydro-3-[[[4-[methyl[2-(4-methyl-1-piperazinyl)acetyl]amino]phenyl]amino]phenylmethylene]-2-oxo-, methyl ester, (3Z)-, ethanesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 656247-17-5
CMF C31 H33 N5 O4

Double bond geometry as shown.



CM 2

CRN 594-45-6
CMF C2 H6 O3 S



L4 ANSWER 5 OF 7 USPATFULL on STN
ACCESSION NUMBER: 2006:68089 USPATFULL
TITLE: Combinations for the treatment of diseases involving cell proliferation
INVENTOR(S): Munzert, Gerd, Ulm, GERMANY, FEDERAL REPUBLIC OF
Steegmaier, Martin, Wien, AUSTRIA
Baum, Anke, Vienna, AUSTRIA
PATENT ASSIGNEE(S): Boehringer Ingelheim International GmbH, Ingelheim, GERMANY, FEDERAL REPUBLIC OF (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2006058311	A1	20060316
APPLICATION INFO.:	US 2005-189540	A1	20050726 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	EP 2004-19361	20040814
	EP 2004-19448	20040817

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: MICHAEL P. MORRIS, BOEHRINGER INGELHEIM CORPORATION, 900 RIDGEBURY ROAD, P. O. BOX 368, RIDGEFIELD, CT, 06877-0368, US
NUMBER OF CLAIMS: 24
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 8 Drawing Page(s)
LINE COUNT: 3176
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed are pharmaceutical compositions for the treatment of diseases which involve cell proliferation. Also disclosed are methods for the treatment of said diseases, comprising co-administration of a compound 1 of Formula (I) ##STR1## wherein the groups L, R.sup.1, R.sup.2, R.sup.3, R.sup.4 and R.sup.5 have the meanings given herein and of an effective amount of an active compound 2 and/or co-treatment with radiation therapy, in a ratio which provides an additive and synergistic effect, and to the combined use of a compound 1 of Formula (I) and of an effective amount of an active compound 2 and/or radiotherapy for the manufacture of corresponding pharmaceutical combination preparations.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 656247-17-5
(preparation of aminopteridinones for use in combination therapy for treatment of cell proliferative diseases)
RN 656247-17-5 USPATFULL
CN 1H-Indole-6-carboxylic acid, 2,3-dihydro-3-[[[4-[methyl[2-(4-methyl-1-piperazinyl)acetyl]amino]phenyl]amino]phenylmethylene]-2-oxo-, methyl ester, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.



L4 ANSWER 6 OF 7 USPATFULL on STN
ACCESSION NUMBER: 2005:63668 USPATFULL
TITLE: Indolinones substituted by heterocycles, the preparation thereof and their use as medicaments
INVENTOR(S): Kley, Joerg, Mittelbiberach, GERMANY, FEDERAL REPUBLIC OF
Hilberg, Frank, Wien, AUSTRIA
Heckel, Armin, Biberach, GERMANY, FEDERAL REPUBLIC OF

Roth, Gerald Juergen, Biberach, GERMANY, FEDERAL REPUBLIC OF
Lehmann-Lintz, Thorsten, Ochsenhausen, GERMANY, FEDERAL REPUBLIC OF
Lotz, Ralf R. H., Schemmerhofen, GERMANY, FEDERAL REPUBLIC OF
Tontsch-Grunt, Ulrike, Baden, AUSTRIA
Van Meel, Jacobus C. A., Moedling, AUSTRIA

PATENT ASSIGNEE(S): Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, GERMANY, FEDERAL REPUBLIC OF (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2005054710	A1	20050310	
	US 7148249	B2	20061212	
APPLICATION INFO.:	US 2003-656863	A1	20030905	(10)

	NUMBER	DATE	
PRIORITY INFORMATION:	DE 2002-10242350	20020912	
	DE 2002-DE10252969	20021114	
	US 2002-414938P	20020930	(60)
	US 2002-430790P	20021204	(60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: MICHAEL P. MORRIS, BOEHRINGER INGELHEIM CORPORATION, 900 RIDGEBURY ROAD, P. O. BOX 368, RIDGEFIELD, CT, 06877-0368
NUMBER OF CLAIMS: 7
EXEMPLARY CLAIM: 1
LINE COUNT: 6107
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to heterocyclically substituted indolinones of general formula ##STR1##

wherein

R.sub.1 to R.sub.5 and X are defined as in claim 1, the tautomers, the diastereomers, the enantiomers, the mixtures thereof, the prodrugs thereof and the salts thereof, particularly the physiologically acceptable salts thereof which have valuable pharmacological properties, in particular an inhibiting effect on various receptor tyrosine kinases and cyclin/CDK complexes and on the proliferation of endothelial cells and various tumour cells, pharmaceutical compositions containing these compounds, their use and processes for preparing them.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 674769-84-7P
(claimed compound; preparation of heteroaryl-substituted aminomethylideneindolinones as cell proliferation inhibitors)
RN 674769-84-7 USPATFULL
CN 1H-Indole-6-carboxylic acid, 3-[(2,3-dihydro-1,4-benzodioxin-6-yl)[[4-[methyl[(4-methyl-1-piperazinyl)acetyl]amino]phenyl]amino]methylene]-2,3-dihydro-2-oxo-, methyl ester, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



IT 674770-51-5P
(preparation of heteroaryl-substituted aminomethylideneindolinones as cell proliferation inhibitors)
RN 674770-51-5 USPATFULL
CN 1H-Indole-6-carboxylic acid, 3-[1,3-benzodioxol-5-yl[[4-[methyl[(4-methyl-1-piperazinyl)acetyl]amino]phenyl]amino]methylene]-2,3-dihydro-2-oxo-, methyl ester, (3Z)-·(9CI) (CA INDEX NAME)

Double bond geometry as described by E or Z.



L4 ANSWER 7 OF 7 USPATFULL on STN
ACCESSION NUMBER: 2005:50434 USPATFULL
TITLE: Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
INVENTOR(S): Stefanic, Martin Friedrich, Warthausen-Birkenhard, GERMANY, FEDERAL REPUBLIC OF
Hilberg, Frank, Wien, AUSTRIA
Munzert, Gerd, Ulm, GERMANY, FEDERAL REPUBLIC OF
Solca, Flavio, Wien, AUSTRIA

	Baum, Anke, Alland, AUSTRIA van Meel, Jacobus C.A., Moedling, AUSTRIA
PATENT ASSIGNEE(S):	Boehringer Ingelheim International GmbH, Ingelheim, GERMANY, FEDERAL REPUBLIC OF (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2005043233	A1	20050224	
APPLICATION INFO.:	US 2004-830147	A1	20040422	(10)

	NUMBER	DATE	
PRIORITY INFORMATION:	EP 2003-9587	20030429	
	EP 2004-508	20040113	
	EP 2004-1171	20040121	
	US 2004-542036P	20040205	(60)

DOCUMENT TYPE:	Utility
FILE SEGMENT:	APPLICATION
LEGAL REPRESENTATIVE:	MICHAEL P. MORRIS, BOEHRINGER INGELHEIM CORPORATION, 900 RIDGEBURY ROAD, P. O. BOX 368, RIDGEFIELD, CT, 06877-0368
NUMBER OF CLAIMS:	30
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	3 Drawing Page(s)
LINE COUNT:	2377

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to a pharmaceutical combination for the treatment of diseases which involves cell proliferation, migration or apoptosis of myeloma cells, or angiogenesis. The invention also relates to a method for the treatment of said diseases, comprising co-administration of effective amounts of specific active compounds and/or co-treatment with radiation therapy, in a ratio which provides an additive and synergistic effect, and to the combined use of these specific compounds and/or radiotherapy for the manufacture of corresponding pharmaceutical combination preparations.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 656247-17-5
(combination of steroid and tyrosine kinase receptor antagonist for treatment of diseases involving myeloma proliferation, migration or apoptosis, or angiogenesis)

RN 656247-17-5 USPATFULL

CN 1H-Indole-6-carboxylic acid, 2,3-dihydro-3-[[[4-[methyl[2-(4-methyl-1-piperazinyl)acetyl]amino]phenyl]amino]phenylmethylene]-2-oxo-, methyl ester, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.



=> d his

```
     (FILE 'HOME' ENTERED AT 10:55:13 ON 13 NOV 2007)

     FILE 'REGISTRY' ENTERED AT 10:55:24 ON 13 NOV 2007
L1             STRUCTURE UPLOADED
L2           6 S L1 FULL

     FILE 'MEDLINE, CAPLUS, WPIDS, USPATFULL' ENTERED AT 10:55:57 ON 13 NOV
     2007
L3          17 S L2
L4           7 S L3 AND CANCER

=> s l3 and combination
L5          10 L3 AND COMBINATION

=> s l5 and "pharmaceutical combination"
L6           4 L5 AND "PHARMACEUTICAL COMBINATION"

=> d l6 1-4 ibib, abs, hitstr

L6   ANSWER 1 OF 4  CAPLUS  COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER:         2004:965067  CAPLUS
DOCUMENT NUMBER:          141:406039
TITLE:                    Combinations for the treatment of diseases involving
                          cell proliferation, migration or apoptosis of myeloma
                          cells, or angiogenesis
INVENTOR(S):              Hilberg, Frank; Solca, Flavio; Stefanic, Martin
                          Friedrich; Baum, Anke; Munzert, Gerd; Van Meel,
                          Jacobus C. A.
PATENT ASSIGNEE(S):       Boehringer Ingelheim International G.m.b.H., Germany;
                          Boehringer Ingelheim Pharma G.m.b.H. & Co. K.-G.
SOURCE:                   PCT Int. Appl., 101 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   2
PATENT INFORMATION:

     PATENT NO.            KIND   DATE        APPLICATION NO.          DATE
     ---------------       ----   --------    --------------------     --------
     WO 2004096224          A2    20041111    WO 2004-EP4363           20040424
     WO 2004096224          A3    20041216
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE,
             GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK,
             LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO,
             NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ,
             TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
             AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
             EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
             SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
             SN, TD, TG
     EP 1473043             A1    20041103    EP 2003-9587             20030429
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
     AU 2004233576          A1    20041111    AU 2004-233576           20040424
     CA 2523868             A1    20041111    CA 2004-2523868          20040424
     EP 1622619             A2    20060208    EP 2004-729366           20040424
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK
     BR 2004009919          A     20060425    BR 2004-9919             20040424
     JP 2006524634          T     20061102    JP 2006-500099           20040424
     MX 2005PA11656         A     20051215    MX 2005-PA11656          20051028
     NO 2005005605          A     20051128    NO 2005-5605             20051128
```

PRIORITY APPLN. INFO.:

EP 2003-9587	A	20030429
EP 2004-508	A	20040113
EP 2004-1171	A	20040121
WO 2004-EP4363	W	20040424

AB The present invention relates to a pharmaceutical combination for the treatment of diseases which involves cell proliferation, migration or apoptosis of myeloma cells, or angiogenesis. The invention also relates to a method for the treatment of said diseases, comprising co-administration of effective amts. of specific active compds. and/or co-treatment with radiation therapy, in a ratio which provides an additive and synergistic effect, and to the combined use of these specific compds. and/or radiotherapy for the manufacture of corresponding pharmaceutical combination prepns. The pharmaceutical combination can include selected protein tyrosine kinase receptor antagonists and further chemotherapeutic or naturally occurring semisynthetic or synthetic agents.

IT 656247-17-5 790241-30-4 790241-31-5
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(drug combinations for diseases involving cell proliferation and migration or apoptosis or angiogenesis including protein tyrosine kinase receptor antagonists and radiotherapy)

RN 656247-17-5 CAPLUS

CN 1H-Indole-6-carboxylic acid, 2,3-dihydro-3-[[[4-[methyl[2-(4-methyl-1-piperazinyl)acetyl]amino]phenyl]amino]phenylmethylene]-2-oxo-, methyl ester, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.



RN 790241-30-4 CAPLUS

CN 1H-Indole-6-carboxylic acid, 2,3-dihydro-3-[[[4-[methyl[(4-methyl-1-piperazinyl)acetyl]amino]phenyl]amino]phenylmethylene]-2-oxo-, methyl ester, (3Z)-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 656247-17-5
CMF C31 H33 N5 O4

Double bond geometry as shown.



CM 2

CRN 75-75-2
CMF C H4 O3 S



RN 790241-31-5 CAPLUS
CN 1H-Indole-6-carboxylic acid, 2,3-dihydro-3-[[[4-[methyl[(4-methyl-1-piperazinyl)acetyl]amino]phenyl]amino]phenylmethylene]-2-oxo-, methyl ester, dihydrochloride, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



●2 HCl

L6 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:930932 CAPLUS
DOCUMENT NUMBER: 141:400905
TITLE: Combination of steroid and tyrosine kinase receptor antagonist for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells, or angiogenesis
INVENTOR(S): Stefanic, Martin; Munzert, Gerd; Hilberg, Frank
PATENT ASSIGNEE(S): Boehringer Ingelheim Pharma GmbH & Co. KG, Germany
SOURCE: Eur. Pat. Appl., 14 pp.

CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1473043	A1	20041103	EP 2003-9587	20030429
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
US 2005043233	A1	20050224	US 2004-830147	20040422
AU 2004233576	A1	20041111	AU 2004-233576	20040424
CA 2523868	A1	20041111	CA 2004-2523868	20040424
WO 2004096224	A2	20041111	WO 2004-EP4363	20040424
WO 2004096224	A3	20041216		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1622619	A2	20060208	EP 2004-729366	20040424
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
BR 2004009919	A	20060425	BR 2004-9919	20040424
CN 1780627	A	20060531	CN 2004-80011544	20040424
JP 2006524634	T	20061102	JP 2006-500099	20040424
ZA 2005006605	A	20060830	ZA 2005-6605	20050818
MX 2005PA11656	A	20051215	MX 2005-PA11656	20051028
NO 2005005605	A	20051128	NO 2005-5605	20051128

PRIORITY APPLN. INFO.:		
EP 2003-9587	A	20030429
EP 2004-508	A	20040113
EP 2004-1171	A	20040121
US 2004-542036P	P	20040205
WO 2004-EP4363	W	20040424

AB The present invention relates to a pharmaceutical combination for the treatment of diseases which involves cell proliferation, migration or apoptosis of myeloma cells, or angiogenesis. The combination comprises the co-administration of a protein tyrosine kinase receptor antagonist and of a steroid.

IT 656247-17-5
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combination of steroid and tyrosine kinase receptor antagonist for treatment of diseases involving myeloma proliferation, migration or apoptosis, or angiogenesis)

RN 656247-17-5 CAPLUS

CN 1H-Indole-6-carboxylic acid, 2,3-dihydro-3-[[[4-[methyl[2-(4-methyl-1-piperazinyl)acetyl]amino]phenyl]amino]phenylmethylene]-2-oxo-, methyl ester, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.



L6 ANSWER 3 OF 4 USPATFULL on STN

ACCESSION NUMBER:	2006:68089 USPATFULL
TITLE:	Combinations for the treatment of diseases involving cell proliferation
INVENTOR(S):	Munzert, Gerd, Ulm, GERMANY, FEDERAL REPUBLIC OF Steegmaier, Martin, Wien, AUSTRIA Baum, Anke, Vienna, AUSTRIA
PATENT ASSIGNEE(S):	Boehringer Ingelheim International GmbH, Ingelheim, GERMANY, FEDERAL REPUBLIC OF (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2006058311	A1	20060316	
APPLICATION INFO.:	US 2005-189540	A1	20050726	(11)

	NUMBER	DATE
PRIORITY INFORMATION:	EP 2004-19361	20040814
	EP 2004-19448	20040817

DOCUMENT TYPE:	Utility
FILE SEGMENT:	APPLICATION
LEGAL REPRESENTATIVE:	MICHAEL P. MORRIS, BOEHRINGER INGELHEIM CORPORATION, 900 RIDGEBURY ROAD, P. O. BOX 368, RIDGEFIELD, CT, 06877-0368, US
NUMBER OF CLAIMS:	24
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	8 Drawing Page(s)
LINE COUNT:	3176

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed are pharmaceutical compositions for the treatment of diseases which involve cell proliferation. Also disclosed are methods for the treatment of said diseases, comprising co-administration of a compound 1 of Formula (I) ##STR1## wherein the groups L, R.sup.1, R.sup.2, R.sup.3, R.sup.4 and R.sup.5 have the meanings given herein and of an effective amount of an active compound 2 and/or co-treatment with radiation therapy, in a ratio which provides an additive and synergistic effect, and to the combined use of a compound 1 of Formula (I) and of an effective amount of an active compound 2 and/or radiotherapy for the manufacture of corresponding pharmaceutical combination preparations.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 656247-17-5
(preparation of aminopteridinones for use in combination therapy for treatment of cell proliferative diseases)

RN 656247-17-5 USPATFULL

CN 1H-Indole-6-carboxylic acid, 2,3-dihydro-3-[[[4-[methyl[2-(4-methyl-1-piperazinyl)acetyl]amino]phenyl]amino]phenylmethylene]-2-oxo-, methyl ester, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.



L6 ANSWER 4 OF 4 USPATFULL on STN

ACCESSION NUMBER: 2005:50434 USPATFULL

TITLE: Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis

INVENTOR(S): Stefanic, Martin Friedrich, Warthausen-Birkenhard, GERMANY, FEDERAL REPUBLIC OF
Hilberg, Frank, Wien, AUSTRIA
Munzert, Gerd, Ulm, GERMANY, FEDERAL REPUBLIC OF
Solca, Flavio, Wien, AUSTRIA
Baum, Anke, Alland, AUSTRIA
van Meel, Jacobus C.A., Moedling, AUSTRIA

PATENT ASSIGNEE(S): Boehringer Ingelheim International GmbH, Ingelheim, GERMANY, FEDERAL REPUBLIC OF (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2005043233	A1	20050224	
APPLICATION INFO.:	US 2004-830147	A1	20040422	(10)

	NUMBER	DATE	
PRIORITY INFORMATION:	EP 2003-9587	20030429	
	EP 2004-508	20040113	
	EP 2004-1171	20040121	
	US 2004-542036P	20040205	(60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: MICHAEL P. MORRIS, BOEHRINGER INGELHEIM CORPORATION, 900 RIDGEBURY ROAD, P. O. BOX 368, RIDGEFIELD, CT, 06877-0368

NUMBER OF CLAIMS: 30

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 3 Drawing Page(s)

LINE COUNT: 2377

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to a pharmaceutical combination for the treatment of diseases which involves cell proliferation, migration or apoptosis of myeloma cells, or angiogenesis. The invention also relates to a method for the treatment of said diseases, comprising co-administration of effective amounts of specific active compounds and/or co-treatment with radiation therapy, in a ratio which provides an additive and synergistic effect, and to the combined use of these specific compounds and/or radiotherapy for the manufacture of corresponding pharmaceutical combination preparations.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 656247-17-5
(combination of steroid and tyrosine kinase receptor antagonist for treatment of diseases involving myeloma proliferation, migration or apoptosis, or angiogenesis)
RN 656247-17-5 USPATFULL
CN 1H-Indole-6-carboxylic acid, 2,3-dihydro-3-[[[4-[methyl[2-(4-methyl-1-piperazinyl)acetyl]amino]phenyl]amino]phenylmethylene]-2-oxo-, methyl ester, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.



=> d his

(FILE 'HOME' ENTERED AT 10:55:13 ON 13 NOV 2007)

FILE 'REGISTRY' ENTERED AT 10:55:24 ON 13 NOV 2007
L1 STRUCTURE UPLOADED
L2 6 S L1 FULL

FILE 'MEDLINE, CAPLUS, WPIDS, USPATFULL' ENTERED AT 10:55:57 ON 13 NOV 2007
L3 17 S L2
L4 7 S L3 AND CANCER
L5 10 S L3 AND COMBINATION
L6 4 S L5 AND "PHARMACEUTICAL COMBINATION"

=> FIL REGISTRY

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	148.89	321.20

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-3.90	-3.90

FILE 'REGISTRY' ENTERED AT 11:28:05 ON 13 NOV 2007

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 12 NOV 2007 HIGHEST RN 953132-99-5
DICTIONARY FILE UPDATES: 12 NOV 2007 HIGHEST RN 953132-99-5

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=> E "4-[(3-CHLORO-4- FLUOROPHENYL)AMINO]-6-{[4-(N,N-DIMETHYLAMINO)-1-OXO-2-BUTEN-L-YL]AMINO}-7-((S)-TETRAHYDROFURAN-3-YLOXY)-QUINAZOLINE"/CN 25

E1 1 4,N-DIMETHYLQUINOLINIUM IODIDE/CN

E2 1 4,STILBENAMINE, N,N-DIMETHYL-2',4'-BIS(PHENYLSULFONYL)-/CN

E3 0 --> 4-(3-CHLORO-4-FLUOROPHENYL)AMINO-6-{4-(N,N-DIMETHYLAMINO)-1-OXO-2-BUTEN- L-YL AMINO}-7-((S)-TETRAHYDROFURAN-3-YLOXY)-QUINAZOLINE/CN

E4 1 4-(((((1,1-DIMETHYLETHYL)OXY)CARBONYL)AMINO)METHYL)BENZOIC ACID/CN

E5 1 4-(((((1-CARBOXY-2-MERCAPTOETHYL)CARBAMOYL)METHOXY)CARBONYL)AMINO)-2-HYDROXYBENZOIC ACID/CN

E6 1 4-(((((1R,2S)-2-(((3AR,4R,9BR)-4-PHENYL-2,3,3A,4,5,9B-HEXAHYDRO-1H-PYRROLO(3,2-C)QUINOLIN-1-YL)CARBONYL)CYCLOHEXYL)AMINO)CARBONYL)AMINO)BENZAMIDE/CN

E7 1 4-(((((5-CYCLOPROPYL-1H-PYRAZOL-3-YL)AMINO)CARBONYL)AMINO)METHYL)BENZENESULFONAMIDE/CN

E8 1 4-(((((9AS)-8-ACETYL-1,7-DIHYDROXY-3-METHOXY-9A-METHYL-9-OXO-9,9A-DIHYDRODIBENZO(B,D)FURAN-4-YL)CARBONYL)AMINO)METHYL)-1-NAPHTHYL N,N-DIETHYLCARBAMATE/CN

E9 1 4-(((((9AS)-8-ACETYL-1,7-DIHYDROXY-3-METHOXY-9A-METHYL-9-OXO-9,9A-DIHYDRODIBENZO(B,D)FURAN-4-YL)CARBONYL)AMINO)METHYL)-2,3,5-TRIMETHYLBENZOIC ACID/CN

E10 1 4-(((((9AS)-8-ACETYL-1,7-DIHYDROXY-3-METHOXY-9A-METHYL-9-OXO-9,9A-DIHYDRODIBENZO(B,D)FURAN-4-YL)CARBONYL)AMINO)METHYL)-2,3,5-TRIMETHYLPHENYL ACETATE/CN

E11 1 4-(((((9AS)-8-ACETYL-1,7-DIHYDROXY-3-METHOXY-9A-METHYL-9-OXO-9,9A-DIHYDRODIBENZO(B,D)FURAN-4-YL)CARBONYL)AMINO)METHYL)-2-NAPHTHOIC ACID/CN

E12 1 4-(((((9AS)-8-ACETYL-1,7-DIHYDROXY-3-METHOXY-9A-METHYL-9-OXO-9,9A-DIHYDRODIBENZO(B,D)FURAN-4-YL)CARBONYL)AMINO)METHYL)-2-NAPHTHYL ACETATE/CN

E13 1 4-(((((9AS)-8-ACETYL-1,7-DIHYDROXY-3-METHOXY-9A-METHYL-9-OXO-9,9A-DIHYDRODIBENZO(B,D)FURAN-4-YL)CARBONYL)AMINO)METHYL)-2-NAPHTHYL N,N-DIMETHYLCARBAMATE/CN

E14 1 4-(((((9AS)-8-ACETYL-1,7-DIHYDROXY-3-METHOXY-9A-METHYL-9-OXO-9,9A-DIHYDRODIBENZO(B,D)FURAN-4-YL)CARBONYL)AMINO)METHYL)-3,5-DIMETHYLPHENYL ACETATE/CN

E15 1 4-(((((FLUOREN-9-YLMETHOXYCARBONYLAMINO))THIOXOMETHYL)AMINO)METHYL)-4-FLUOROPIPERIDINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER/CN

E16 1 4-(((((P-NITROBENZYL)OXY)CARBONYL)AMINO)METHYL)ANILINE/CN

E17 1 4-((((1,1'-BIPHENYL)-4-YL)CARBONYL)AMINO)-2-(METHYLTHIO)-1-PHENYL-1H-IMIDAZOLE-5-CARBOXYLIC ACID ETHYL ESTER/CN

E18 1 4-((((1,1-DIMETHYLETHYL)DIMETHYLSILYL)OXY)METHYL)BENZENAMINE/CN

E19 1 4-((((1,1-DIMETHYLETHYL)DIMETHYLSILYL)OXY)METHYL)PHENOL/CN

E20 1 4-((((1,1-DIMETHYLETHYL)DIMETHYLSILYL)OXY)METHYL)PYRIDINE/CN

E21 1 4-((((1,1-DIMETHYLETHYL)OXY)CARBONYL)AMINO)-2-PHENYLBUTANOIC ACID/CN

E22 1 4-((((1,1-DIMETHYLETHYL)OXY)CARBONYL)AMINO)-3-PHENYLBUTANOIC ACID/CN

```
E23             1
4-((((1,1-DIMETHYLETHYL)OXY)CARBONYL)AMINO)-4-(3-METHYLPHENYL)BUTANOIC ACID/CN
E24             1       4-((((1,1-DIMETHYLETHYL)OXY)CARBONYL)AMINO)-4-PHENYLBUTANOIC
ACID/CN
E25             1       4-((((1,1-DIMETHYLETHYL)OXY)CARBONYL)AMINO)CYCLOHEXANECARBOXYLIC
ACID/CN

=> E
"4-[(3-CHLORO-4-FLUOROPHENYL)AMINO]-6-{[4-(N,N-DIMETHYLAMINO)-1-OXO-2-BUTEN-1-YL]AMI
NO}-7-((S)-TETRAHYDROFURAN-3-YLOXY)-QUINAZOLINE"/CN 25
E1              1       4,N-DIMETHYLQUINOLINIUM IODIDE/CN
E2              1       4,STILBENAMINE, N,N-DIMETHYL-2',4'-BIS(PHENYLSULFONYL)-/CN
E3              0 -->
4-(3-CHLORO-4-FLUOROPHENYL)AMINO-6-{4-(N,N-DIMETHYLAMINO)-1-OXO-2-BUTEN-1-YL
AMINO}-7-((S)-TETRAHYDROFURAN-3-YLOXY)-QUINAZOLINE/CN
E4              1       4-(((((1,1-DIMETHYLETHYL)OXY)CARBONYL)AMINO)METHYL)BENZOIC
ACID/CN
E5              1
4-(((((1-CARBOXY-2-MERCAPTOETHYL)CARBAMOYL)METHOXY)CARBONYL)AMINO)-2-HYDROXYBENZOIC
ACID/CN
E6              1
4-(((((1R,2S)-2-(((3AR,4R,9BR)-4-PHENYL-2,3,3A,4,5,9B-HEXAHYDRO-1H-PYRROLO(3,2-C)QUI
NOLIN-1-YL)CARBONYL)CYCLOHEXYL)AMINO)CARBONYL)AMINO)BENZAMIDE/CN
E7              1
4-(((((5-CYCLOPROPYL-1H-PYRAZOL-3-YL)AMINO)CARBONYL)AMINO)METHYL)BENZENESULFONAMIDE/
CN
E8              1
4-(((((9AS)-8-ACETYL-1,7-DIHYDROXY-3-METHOXY-9A-METHYL-9-OXO-9,9A-DIHYDRODIBENZO(B,D
)FURAN-4-YL)CARBONYL)AMINO)METHYL)-1-NAPHTHYL N,N-DIETHYLCARBAMATE/CN
E9              1
4-(((((9AS)-8-ACETYL-1,7-DIHYDROXY-3-METHOXY-9A-METHYL-9-OXO-9,9A-DIHYDRODIBENZO(B,D
)FURAN-4-YL)CARBONYL)AMINO)METHYL)-2,3,5-TRIMETHYLBENZOIC ACID/CN
E10             1
4-(((((9AS)-8-ACETYL-1,7-DIHYDROXY-3-METHOXY-9A-METHYL-9-OXO-9,9A-DIHYDRODIBENZO(B,D
)FURAN-4-YL)CARBONYL)AMINO)METHYL)-2,3,5-TRIMETHYLPHENYL ACETATE/CN
E11             1
4-(((((9AS)-8-ACETYL-1,7-DIHYDROXY-3-METHOXY-9A-METHYL-9-OXO-9,9A-DIHYDRODIBENZO(B,D
)FURAN-4-YL)CARBONYL)AMINO)METHYL)-2-NAPHTHOIC ACID/CN
E12             1
4-(((((9AS)-8-ACETYL-1,7-DIHYDROXY-3-METHOXY-9A-METHYL-9-OXO-9,9A-DIHYDRODIBENZO(B,D
)FURAN-4-YL)CARBONYL)AMINO)METHYL)-2-NAPHTHYL ACETATE/CN
E13             1
4-(((((9AS)-8-ACETYL-1,7-DIHYDROXY-3-METHOXY-9A-METHYL-9-OXO-9,9A-DIHYDRODIBENZO(B,D
)FURAN-4-YL)CARBONYL)AMINO)METHYL)-2-NAPHTHYL N,N-DIMETHYLCARBAMATE/CN
E14             1
4-(((((9AS)-8-ACETYL-1,7-DIHYDROXY-3-METHOXY-9A-METHYL-9-OXO-9,9A-DIHYDRODIBENZO(B,D
)FURAN-4-YL)CARBONYL)AMINO)METHYL)-3,5-DIMETHYLPHENYL ACETATE/CN
E15             1
4-(((((FLUOREN-9-YLMETHOXYCARBONYLAMINO))THIOXOMETHYL)AMINO)METHYL)-4-FLUOROPIPERIDI
NE-1-CARBOXYLIC ACID TERT-BUTYL ESTER/CN
E16             1       4-(((((P-NITROBENZYL)OXY)CARBONYL)AMINO)METHYL)ANILINE/CN
E17             1
4-((((1,1'-BIPHENYL)-4-YL)CARBONYL)AMINO)-2-(METHYLTHIO)-1-PHENYL-1H-IMIDAZOLE-5-CAR
BOXYLIC ACID ETHYL ESTER/CN
E18             1       4-((((1,1-DIMETHYLETHYL)DIMETHYLSILYL)OXY)METHYL)BENZENAMINE/CN
E19             1       4-((((1,1-DIMETHYLETHYL)DIMETHYLSILYL)OXY)METHYL)PHENOL/CN
E20             1       4-((((1,1-DIMETHYLETHYL)DIMETHYLSILYL)OXY)METHYL)PYRIDINE/CN
E21             1       4-((((1,1-DIMETHYLETHYL)OXY)CARBONYL)AMINO)-2-PHENYLBUTANOIC
ACID/CN
E22             1       4-((((1,1-DIMETHYLETHYL)OXY)CARBONYL)AMINO)-3-PHENYLBUTANOIC
ACID/CN
E23             1
4-((((1,1-DIMETHYLETHYL)OXY)CARBONYL)AMINO)-4-(3-METHYLPHENYL)BUTANOIC ACID/CN
E24             1       4-((((1,1-DIMETHYLETHYL)OXY)CARBONYL)AMINO)-4-PHENYLBUTANOIC
ACID/CN
```

E25 1 4-((((1,1-DIMETHYLETHYL)OXY)CARBONYL)AMINO)CYCLOHEXANECARBOXYLIC ACID/CN

=>
Uploading C:\Program Files\Stnexp\Queries\10830147_specie2.str



chain nodes :
11 18 19 20 21 22 23 24 25 26 27 28 34
ring nodes :
1 2 3 4 5 6 7 8 9 10 12 13 14 15 16 17 29 30 31 32 33
chain bonds :
3-11 8-20 9-28 11-12 14-19 15-18 20-21 21-22 21-34 22-23 23-24 24-25 25-26 25-27 28-29
ring bonds :
1-2 1-6 2-3 3-4 4-5 4-7 5-6 5-10 7-8 8-9 9-10 12-13 12-17 13-14 14-15 15-16 16-17 29-30 29-33 30-31 31-32 32-33
exact/norm bonds :
3-11 8-20 9-28 11-12 20-21 21-34 24-25 28-29 29-30 29-33 30-31 31-32 32-33
exact bonds :
14-19 15-18 21-22 22-23 23-24 25-26 25-27
normalized bonds :
1-2 1-6 2-3 3-4 4-5 4-7 5-6 5-10 7-8 8-9 9-10 12-13 12-17 13-14 14-15 15-16 16-17

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:CLASS 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:CLASS 19:CLASS
20:CLASS 21:CLASS 22:CLASS 23:CLASS 24:CLASS 25:CLASS 26:CLASS 27:CLASS
28:CLASS 29:Atom 30:Atom 31:Atom 32:Atom 33:Atom 34:CLASS

Stereo Bonds:

29-28 (Single Wedge).

Stereo Chiral Centers:

29 (Parity=Don't Care)

Stereo RSS Sets:

Type=Relative (Default). 1 Nodes= 29

L7 STRUCTURE UPLOADED

```
=> d l7
L7 HAS NO ANSWERS
L7              STR

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

Structure attributes must be viewed using STN Express query preparation.


=> s l7 full
FULL SEARCH INITIATED 11:33:50 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -       75 TO ITERATE

100.0% PROCESSED       75 ITERATIONS                                 6 ANSWERS
SEARCH TIME: 00.00.01

L8            6 SEA SSS FUL L7

=> d his

     (FILE 'HOME' ENTERED AT 10:55:13 ON 13 NOV 2007)

     FILE 'REGISTRY' ENTERED AT 10:55:24 ON 13 NOV 2007
L1              STRUCTURE UPLOADED
L2            6 S L1 FULL

     FILE 'MEDLINE, CAPLUS, WPIDS, USPATFULL' ENTERED AT 10:55:57 ON 13 NOV
     2007
L3           17 S L2
L4            7 S L3 AND CANCER
L5           10 S L3 AND COMBINATION
L6            4 S L5 AND "PHARMACEUTICAL COMBINATION"

     FILE 'REGISTRY' ENTERED AT 11:28:05 ON 13 NOV 2007
                E "4-[(3-CHLORO-4- FLUOROPHENYL)AMINO]-6-{[4-(N,N-DIMETHYLAMINO
                E "4-[(3-CHLORO-4-FLUOROPHENYL)AMINO]-6-{[4-(N,N-DIMETHYLAMINO)
L7              STRUCTURE UPLOADED
L8            6 S L7 FULL

=> file medline caplus wpids uspatfull
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                   176.15     497.35

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                     0.00      -3.90

FILE 'MEDLINE' ENTERED AT 11:34:13 ON 13 NOV 2007

FILE 'CAPLUS' ENTERED AT 11:34:13 ON 13 NOV 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'WPIDS' ENTERED AT 11:34:13 ON 13 NOV 2007
COPYRIGHT (C) 2007 THE THOMSON CORPORATION

FILE 'USPATFULL' ENTERED AT 11:34:13 ON 13 NOV 2007
CA INDEXING COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

=> s l8
SAMPLE SEARCH INITIATED 11:34:18 FILE 'WPIDS'
SAMPLE SCREEN SEARCH COMPLETED -        1 TO ITERATE
```

100.0% PROCESSED 1 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 1 TO 40
PROJECTED ANSWERS: 0 TO 0

L9 34 L8

=> s l3 and l9
L10 4 L3 AND L9

=> d l10 1-4 ibib, abs, hitstr

L10 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2007:537782 CAPLUS
DOCUMENT NUMBER: 146:514717
TITLE: Combination treatment of cancer comprising EGFR/HER2 inhibitors
INVENTOR(S): Solca, Flavio; Amelsberg, Andree; Stehle, Gerd; Van Meel, Jacobus C. A.; Baum, Anke
PATENT ASSIGNEE(S): Boehringer Ingelheim International GmbH, Germany; Boehringer Ingelheim Pharma GmbH & Co. KG
SOURCE: PCT Int. Appl., 107pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007054551	A1	20070518	WO 2006-EP68314	20061109

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: EP 2005-110669 A 20051111
OTHER SOURCE(S): MARPAT 146:514717
GI



I

AB The invention discloses a therapy of cancer comprising co-administration

to a person in need of such treatment and/or co-treatment of a person in need of such treatment with effective amts. of (1) a compound I (Ra = benzyl, 1-phenylethyl, 3-chloro-4-fluorophenyl; Rb = H, C1-4 alkyl; Rc = cyclopropylmethoxy, cyclobutoxy, etc.; Rd = dimethylamino, N-cyclopropyl-N-methylamino, etc.); and (2) at least a further chemotherapeutic agent; optionally in combination with radiotherapy, radioimmunotherapy and/or tumor resection by surgery. The invention further discloses corresponding medicaments and the preparation thereof.

IT 439081-17-1 439081-17-1D, derivs., salts, and enantiomers 439081-18-2 439081-18-2D, derivs., salts, and enantiomers 656247-17-5 656247-17-5D, salts and metabolites
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(EGFR/HER2 inhibitor combination treatment for cancer)

RN 439081-17-1 CAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[[(3R)-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4-(dimethylamino)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 439081-17-1 CAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[[(3R)-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4-(dimethylamino)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 439081-18-2 CAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[[(3S)-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4-(dimethylamino)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 439081-18-2 CAPLUS
CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[[(3S)-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4-(dimethylamino)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 656247-17-5 CAPLUS
CN 1H-Indole-6-carboxylic acid, 2,3-dihydro-3-[[[4-[methyl[2-(4-methyl-1-piperazinyl)acetyl]amino]phenyl]amino]phenylmethylene]-2-oxo-, methyl ester, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.



RN 656247-17-5 CAPLUS
CN 1H-Indole-6-carboxylic acid, 2,3-dihydro-3-[[[4-[methyl[2-(4-methyl-1-piperazinyl)acetyl]amino]phenyl]amino]phenylmethylene]-2-oxo-, methyl ester, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:167588 CAPLUS
DOCUMENT NUMBER: 144:254148
TITLE: Aminopteridinones as anticancer agents, their preparation, pharmaceutical compositions, and use in therapy
INVENTOR(S): Munzert, Gerd; Steegmaier, Martin; Baum, Anke
PATENT ASSIGNEE(S): Boehringer Ingelheim International G.m.b.H., Germany; Boehringer Ingelheim Pharma G.m.b.H. & Co. K.-G.
SOURCE: PCT Int. Appl., 158 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2006018182	A1	20060223	WO 2005-EP8623		20050809
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
US 2006058311	A1	20060316	US 2005-189540		20050726
AU 2005274384	A1	20060223	AU 2005-274384		20050809
CA 2576269	A1	20060223	CA 2005-2576269		20050809
EP 1827441	A1	20070905	EP 2005-770228		20050809
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BA, HR, YU					
CN 101039673	A	20070919	CN 2005-80035272		20050809
IN 2007DN00888	A	20070803	IN 2007-DN888		20070202
KR 2007050478	A	20070515	KR 2007-705955		20070314
PRIORITY APPLN. INFO.:			EP 2004-19361	A	20040814
			EP 2004-19448	A	20040817
			WO 2005-EP8623	W	20050809

OTHER SOURCE(S): MARPAT 144:254148
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention relates to a group of aminopteridinones I, which are useful for the treatment of diseases which involve cell proliferation. In compds. I, R1 and R2 are independently selected from H and (un)substituted C1-6 alkyl, or R1 and R2 together form a 2- to 5-membered alkylene bridge, optionally containing 1 or 2 heteroatoms; R3 is (un)substituted C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C6-14 aryl, etc.; R4 is H, OH, CN, halo, (un)substituted amino, (un)substituted C1-6 alkyl, C1-5 alkoxy, etc.; L is (un)substituted C2-10 alkylene, (un)substituted C2-10 alkenylene, (un)substituted C6-14 arylene, etc.; R5 is (un)substituted morpholinyl, (un)substituted piperidinyl, (un)substituted piperazinyl, (un)substituted piperazinylcarbonyl, (un)substituted pyrrolidinyl, (un)substituted thiomorpholinyl, etc.; n is 0 or 1; and m is 1 or 2; including tautomers, stereoisomers, salts, solvates, polymorphs, and prodrugs thereof. The invention also relates to the preparation of I, pharmaceutical compns. comprising a compound I, at least one other therapeutic agent, optionally with one or more pharmaceutically acceptable excipients, as well as to the use of the compns. for the treatment of diseases which involve cell proliferation, migration or apoptosis of cancer cells, or angiogenesis. Esterification of (R)-2-aminobutyric acid and reductive condensation with cyclopentanone gave cyclopentylamine II, which underwent regioselective substitution of 2,4-dichloro-5-nitropyrimidine and reductive heterocyclization to form pteridinone III. N-Methylation of III followed by substitution with 4-amino-3-methoxybenzoic acid and amidation with 1-methyl-4-aminopiperidine resulted in the formation of aminopteridinone IV. A combination of suboptimal doses of irinotecan and compound IV shows an additive/synergistic effect in a human colon carcinoma model and is well tolerated. Meanwhile, compound IV acts at least additively with docetaxel in a human non-small cell lung carcinoma model and not antagonistically with gemcitabine in a human adenocarcinoma model.

IT 439081-18-2 656247-17-5
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(preparation of aminopteridinones for use in combination therapy for treatment of cell proliferative diseases)

RN 439081-18-2 CAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[[(3S)-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4-(dimethylamino)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 656247-17-5 CAPLUS

CN 1H-Indole-6-carboxylic acid, 2,3-dihydro-3-[[[4-[methyl[2-(4-methyl-1-piperazinyl)acetyl]amino]phenyl]amino]phenylmethylene]-2-oxo-, methyl ester, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:965067 CAPLUS
DOCUMENT NUMBER: 141:406039
TITLE: Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells, or angiogenesis
INVENTOR(S): Hilberg, Frank; Solca, Flavio; Stefanic, Martin Friedrich; Baum, Anke; Munzert, Gerd; Van Meel, Jacobus C. A.
PATENT ASSIGNEE(S): Boehringer Ingelheim International G.m.b.H., Germany; Boehringer Ingelheim Pharma G.m.b.H. & Co. K.-G.
SOURCE: PCT Int. Appl., 101 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004096224	A2	20041111	WO 2004-EP4363	20040424
WO 2004096224	A3	20041216		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1473043	A1	20041103	EP 2003-9587	20030429
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
AU 2004233576	A1	20041111	AU 2004-233576	20040424
CA 2523868	A1	20041111	CA 2004-2523868	20040424
EP 1622619	A2	20060208	EP 2004-729366	20040424
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
BR 2004009919	A	20060425	BR 2004-9919	20040424
JP 2006524634	T	20061102	JP 2006-500099	20040424
MX 2005PA11656	A	20051215	MX 2005-PA11656	20051028
NO 2005005605	A	20051128	NO 2005-5605	20051128

PRIORITY APPLN. INFO.:

EP 2003-9587	A	20030429
EP 2004-508	A	20040113
EP 2004-1171	A	20040121
WO 2004-EP4363	W	20040424

AB The present invention relates to a pharmaceutical combination for the treatment of diseases which involves cell proliferation, migration or apoptosis of myeloma cells, or angiogenesis. The invention also relates to a method for the treatment of said diseases, comprising co-administration of effective amts. of specific active compds. and/or co-treatment with radiation therapy, in a ratio which provides an additive and synergistic effect, and to the combined use of these specific compds. and/or radiotherapy for the manufacture of corresponding pharmaceutical combination prepns. The pharmaceutical combination can include selected protein tyrosine kinase receptor antagonists and further chemotherapeutic or naturally occurring semisynthetic or synthetic agents.

IT 439081-18-2 656247-17-5 790241-30-4
790241-31-5
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(drug combinations for diseases involving cell proliferation and migration or apoptosis or angiogenesis including protein tyrosine kinase receptor antagonists and radiotherapy)

RN 439081-18-2 CAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[[(3S)-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4-(dimethylamino)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 656247-17-5 CAPLUS

CN 1H-Indole-6-carboxylic acid, 2,3-dihydro-3-[[[4-[methyl[2-(4-methyl-1-piperazinyl)acetyl]amino]phenyl]amino]phenylmethylene]-2-oxo-, methyl ester, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.



RN 790241-30-4 CAPLUS
CN 1H-Indole-6-carboxylic acid, 2,3-dihydro-3-[[[4-[methyl[(4-methyl-1-piperazinyl)acetyl]amino]phenyl]amino]phenylmethylene]-2-oxo-, methyl ester, (3Z)-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 656247-17-5
CMF C31 H33 N5 O4

Double bond geometry as shown.



CM 2

CRN 75-75-2
CMF C H4 O3 S



RN 790241-31-5 CAPLUS
CN 1H-Indole-6-carboxylic acid, 2,3-dihydro-3-[[[4-[methyl[(4-methyl-1-piperazinyl)acetyl]amino]phenyl]amino]phenylmethylene]-2-oxo-, methyl ester, dihydrochloride, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



●2 HCl

L10 ANSWER 4 OF 4 USPATFULL on STN
ACCESSION NUMBER: 2006:68089 USPATFULL
TITLE: Combinations for the treatment of diseases involving cell proliferation
INVENTOR(S): Munzert, Gerd, Ulm, GERMANY, FEDERAL REPUBLIC OF
Steegmaier, Martin, Wien, AUSTRIA
Baum, Anke, Vienna, AUSTRIA
PATENT ASSIGNEE(S): Boehringer Ingelheim International GmbH, Ingelheim, GERMANY, FEDERAL REPUBLIC OF (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2006058311	A1	20060316	
APPLICATION INFO.:	US 2005-189540	A1	20050726	(11)

	NUMBER	DATE
PRIORITY INFORMATION:	EP 2004-19361	20040814
	EP 2004-19448	20040817

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: MICHAEL P. MORRIS, BOEHRINGER INGELHEIM CORPORATION, 900 RIDGEBURY ROAD, P. O. BOX 368, RIDGEFIELD, CT, 06877-0368, US
NUMBER OF CLAIMS: 24
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 8 Drawing Page(s)
LINE COUNT: 3176
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Disclosed are pharmaceutical compositions for the treatment of diseases which involve cell proliferation. Also disclosed are methods for the treatment of said diseases, comprising co-administration of a compound 1 of Formula (I) ##STR1## wherein the groups L, R.sup.1, R.sup.2, R.sup.3, R.sup.4 and R.sup.5 have the meanings given herein and of an effective amount of an active compound 2 and/or co-treatment with radiation therapy, in a ratio which provides an additive and synergistic effect, and to the combined use of a compound 1 of Formula (I) and of an effective amount of an active compound 2 and/or radiotherapy for the manufacture of corresponding pharmaceutical combination preparations.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 439081-18-2 656247-17-5
(preparation of aminopteridinones for use in combination therapy for treatment of cell proliferative diseases)
RN 439081-18-2 USPATFULL
CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[[(3S)-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4-(dimethylamino)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 656247-17-5 USPATFULL
CN 1H-Indole-6-carboxylic acid, 2,3-dihydro-3-[[[4-[methyl[2-(4-methyl-1-piperazinyl)acetyl]amino]phenyl]amino]phenylmethylene]-2-oxo-, methyl ester, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.



=> d his

(FILE 'HOME' ENTERED AT 10:55:13 ON 13 NOV 2007)

FILE 'REGISTRY' ENTERED AT 10:55:24 ON 13 NOV 2007
L1 STRUCTURE UPLOADED
L2 6 S L1 FULL

FILE 'MEDLINE, CAPLUS, WPIDS, USPATFULL' ENTERED AT 10:55:57 ON 13 NOV 2007
L3 17 S L2
L4 7 S L3 AND CANCER
L5 10 S L3 AND COMBINATION
L6 4 S L5 AND "PHARMACEUTICAL COMBINATION"

FILE 'REGISTRY' ENTERED AT 11:28:05 ON 13 NOV 2007
E "4-[(3-CHLORO-4- FLUOROPHENYL)AMINO]-6-{[4-(N,N-DIMETHYLAMINO
E "4-[(3-CHLORO-4-FLUOROPHENYL)AMINO]-6-{[4-(N,N-DIMETHYLAMINO)
L7 STRUCTURE UPLOADED
L8 6 S L7 FULL

FILE 'MEDLINE, CAPLUS, WPIDS, USPATFULL' ENTERED AT 11:34:13 ON 13 NOV 2007
L9 34 S L8
L10 4 S L3 AND L9

```
=> s l9 and (cancer or tumor)
L11           9 L9 AND (CANCER OR TUMOR)

=> s l11 and combination
L12           7 L11 AND COMBINATION

=> d l12 1-7 ibib, abs, hitstr

L12  ANSWER 1 OF 7  CAPLUS  COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER:         2007:537782  CAPLUS
DOCUMENT NUMBER:          146:514717
TITLE:                    Combination treatment of cancer
                          comprising EGFR/HER2 inhibitors
INVENTOR(S):              Solca, Flavio; Amelsberg, Andree; Stehle, Gerd; Van
                          Meel, Jacobus C. A.; Baum, Anke
PATENT ASSIGNEE(S):       Boehringer Ingelheim International GmbH, Germany;
                          Boehringer Ingelheim Pharma GmbH & Co. KG
SOURCE:                   PCT Int. Appl., 107pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.           KIND   DATE        APPLICATION NO.          DATE
     ---------------      ----   --------    --------------------     --------
     WO 2007054551         A1    20070518    WO 2006-EP68314          20061109
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN,
             KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK,
             MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO,
             RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT,
             TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
         RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
             IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
             CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
             GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
             KG, KZ, MD, RU, TJ, TM
PRIORITY APPLN. INFO.:                          EP 2005-110669      A  20051111
OTHER SOURCE(S):          MARPAT 146:514717
GI
```



I

AB The invention discloses a therapy of cancer comprising co-administration to a person in need of such treatment and/or co-treatment of a person in need of such treatment with effective amts. of (1) a compound I (Ra = benzyl, 1-phenylethyl, 3-chloro-4-fluorophenyl; Rb = H, C1-4 alkyl; Rc = cyclopropylmethoxy, cyclobutoxy, etc.; Rd = dimethylamino, N-cyclopropyl-N-methylamino, etc.); and (2) at least a further chemotherapeutic agent; optionally in combination with radiotherapy, radioimmunotherapy and/or tumor resection by surgery. The invention further discloses corresponding medicaments and

the preparation thereof.

IT 439081-17-1 439081-17-1D, derivs., salts, and enantiomers 439081-18-2 439081-18-2D, derivs., salts, and enantiomers
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(EGFR/HER2 inhibitor combination treatment for cancer)

RN 439081-17-1 CAPLUS
CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[[(3R)-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4-(dimethylamino)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 439081-17-1 CAPLUS
CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[[(3R)-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4-(dimethylamino)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 439081-18-2 CAPLUS
CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[[(3S)-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4-(dimethylamino)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 439081-18-2 CAPLUS
CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[[(3S)-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4-(dimethylamino)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2007:140029 CAPLUS
DOCUMENT NUMBER: 146:453828
TITLE: Dual inhibition of ErbB1 (EGFR/HER1) and ErbB2 (HER2/neu)
AUTHOR(S): Reid, Alison; Vidal, Laura; Shaw, Heather; de Bono, Johann
CORPORATE SOURCE: Centre for Cancer Therapeutics, The Institute of Cancer Research, Royal Marsden Hospital, Surrey, SM2 5PT, UK
SOURCE: European Journal of Cancer (2007), 43(3), 481-489
CODEN: EJCAEL; ISSN: 0959-8049
PUBLISHER: Elsevier Ltd.
DOCUMENT TYPE: Journal; General Review
LANGUAGE: English
AB A review. Targeting of epidermal growth factor receptor (EGFR) and HER2 is a proven anti-cancer strategy. However, heterodimerization, compensatory crosstalk' and redundancy exist in the ErbB network, and there is therefore a sound scientific rationale for dual inhibition of EGFR and HER2. Trials of approved agents in combination, for example trastuzumab and cetuximab, are underway. There is also a new generation of small mol. tyrosine kinase inhibitors (TKIs) and monoclonal antibodies (mABs) that target two or more ErbB receptors. Lapatinib, a TKI of EGFR and HER2, has shown clin. benefit in trastuzumab refractory

breast cancer and is poised for FDA approval. Other agents include BIBW-2992 and HKI-272, irreversible TKIs of EGFR and HER2, and pertuzumab, a heterodimerization inhibitor of EGFR and HER2.

IT 439081-18-2
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(BIBW-2992 might cause dual inhibition of ErbB1 or ErbB2 receptor and might be useful treatment in breast cancer patient)

RN 439081-18-2 CAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[[(3S)-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4-(dimethylamino)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



REFERENCE COUNT: 82 THERE ARE 82 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2006:252051 CAPLUS
DOCUMENT NUMBER: 146:19497
TITLE: Combination of EGFR/HER2 TK inhibition through BIBW 2992 and BIBW 2669 with radiation in the human squamous cell carcinoma cell line FaDu
AUTHOR(S): Schuetze, Christina; Krause, Mechthild; Doerfler, Annegret; Zips, Daniel; Solca, Flavio; Baumann, Michael
CORPORATE SOURCE: Klinik und Poliklinik fuer Strahlentherapie und Radioonkologie, TU Dresden, Dresden, Germany
SOURCE: Experimentelle Strahlentherapie und Klinische Strahlenbiologie (2006), 15, 134-139
CODEN: ESKSF9; ISSN: 1432-864X
PUBLISHER: Prof. Dr. Michael Baumann, Prof. Dr. Ekkehard Dikomey, PD Dr. Cordula Petersen, Dr. Annette Raabe
DOCUMENT TYPE: Journal
LANGUAGE: German

AB The effect of the new tyrosine kinase inhibitors BIBW 2992 and BIBW 2669 on the human FaDu squamous cell carcinoma was investigated with and without irradiation Cell proliferation, clonogenic cell survival, cell cycle distribution in vitro, and tumor growth delay were studied. Both the inhibitors of the epidermal growth factor receptor showed antiproliferating effect in vitro and in vivo combined with blocking the cells in the G0/G1 phase of the cell cycle. Sensitization to irradiation by BIBW 2992 was found in vitro. Treatment with BIBW 2992 and BIBW 2669 after a single dose of irradiation resulted in growth delay of tumors addnl. to the effect of irradiation

IT 439081-18-2
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combination of EGFR/HER2 tyrosine kinase inhibition by BIBW 2992 and BIBW 2669 with radiation in squamous cell carcinoma)

RN 439081-18-2 CAPLUS
CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[[(3S)-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4-(dimethylamino)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:167588 CAPLUS
DOCUMENT NUMBER: 144:254148
TITLE: Aminopteridinones as anticancer agents, their preparation, pharmaceutical compositions, and use in therapy
INVENTOR(S): Munzert, Gerd; Steegmaier, Martin; Baum, Anke
PATENT ASSIGNEE(S): Boehringer Ingelheim International G.m.b.H., Germany; Boehringer Ingelheim Pharma G.m.b.H. & Co. K.-G.
SOURCE: PCT Int. Appl., 158 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006018182	A1	20060223	WO 2005-EP8623	20050809
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
US 2006058311	A1	20060316	US 2005-189540	20050726
AU 2005274384	A1	20060223	AU 2005-274384	20050809
CA 2576269	A1	20060223	CA 2005-2576269	20050809
EP 1827441	A1	20070905	EP 2005-770228	20050809
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BA, HR, YU				
CN 101039673	A	20070919	CN 2005-80035272	20050809
IN 2007DN00888	A	20070803	IN 2007-DN888	20070202

KR 2007050478	A	20070515	KR 2007-705955		20070314
PRIORITY APPLN. INFO.:			EP 2004-19361	A	20040814
			EP 2004-19448	A	20040817
			WO 2005-EP8623	W	20050809

OTHER SOURCE(S): MARPAT 144:254148
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention relates to a group of aminopteridinones I, which are useful for the treatment of diseases which involve cell proliferation. In compds. I, R1 and R2 are independently selected from H and (un)substituted C1-6 alkyl, or R1 and R2 together form a 2- to 5-membered alkylene bridge, optionally containing 1 or 2 heteroatoms; R3 is (un)substituted C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C6-14 aryl, etc.; R4 is H, OH, CN, halo, (un)substituted amino, (un)substituted C1-6 alkyl, C1-5 alkoxy, etc.; L is (un)substituted C2-10 alkylene, (un)substituted C2-10 alkenylene, (un)substituted C6-14 arylene, etc.; R5 is (un)substituted morpholinyl, (un)substituted piperidinyl, (un)substituted piperazinyl, (un)substituted piperazinylcarbonyl, (un)substituted pyrrolidinyl, (un)substituted thiomorpholinyl, etc.; n is 0 or 1; and m is 1 or 2; including tautomers, stereoisomers, salts, solvates, polymorphs, and prodrugs thereof. The invention also relates to the preparation of I, pharmaceutical compns. comprising a compound I, at least one other therapeutic agent, optionally with one or more pharmaceutically acceptable excipients, as well as to the use of the compns. for the treatment of diseases which involve cell proliferation, migration or apoptosis of cancer cells, or angiogenesis. Esterification of (R)-2-aminobutyric acid and reductive condensation with cyclopentanone gave cyclopentylamine II, which underwent regioselective substitution of 2,4-dichloro-5-nitropyrimidine and reductive heterocyclization to form pteridinone III. N-Methylation of III followed by substitution with 4-amino-3-methoxybenzoic acid and amidation with 1-methyl-4-aminopiperidine resulted in the formation of aminopteridinone IV. A combination of suboptimal doses of irinotecan and compound IV shows an additive/synergistic effect in a human colon carcinoma model and is well tolerated. Meanwhile, compound IV acts at least additively with docetaxel in a human non-small cell lung carcinoma model and not antagonistically with gemcitabine in a human adenocarcinoma model.

IT 439081-18-2
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(preparation of aminopteridinones for use in combination therapy for treatment of cell proliferative diseases)

RN 439081-18-2 CAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[[(3S)-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4-(dimethylamino)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:965067 CAPLUS
DOCUMENT NUMBER: 141:406039
TITLE: Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells, or angiogenesis
INVENTOR(S): Hilberg, Frank; Solca, Flavio; Stefanic, Martin Friedrich; Baum, Anke; Munzert, Gerd; Van Meel, Jacobus C. A.
PATENT ASSIGNEE(S): Boehringer Ingelheim International G.m.b.H., Germany; Boehringer Ingelheim Pharma G.m.b.H. & Co. K.-G.
SOURCE: PCT Int. Appl., 101 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004096224	A2	20041111	WO 2004-EP4363	20040424
WO 2004096224	A3	20041216		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1473043	A1	20041103	EP 2003-9587	20030429
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
AU 2004233576	A1	20041111	AU 2004-233576	20040424
CA 2523868	A1	20041111	CA 2004-2523868	20040424
EP 1622619	A2	20060208	EP 2004-729366	20040424
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
BR 2004009919	A	20060425	BR 2004-9919	20040424
JP 2006524634	T	20061102	JP 2006-500099	20040424
MX 2005PA11656	A	20051215	MX 2005-PA11656	20051028
NO 2005005605	A	20051128	NO 2005-5605	20051128
PRIORITY APPLN. INFO.:			EP 2003-9587 A	20030429

EP 2004-508	A	20040113
EP 2004-1171	A	20040121
WO 2004-EP4363	W	20040424

AB The present invention relates to a pharmaceutical combination for the treatment of diseases which involves cell proliferation, migration or apoptosis of myeloma cells, or angiogenesis. The invention also relates to a method for the treatment of said diseases, comprising co-administration of effective amts. of specific active compds. and/or co-treatment with radiation therapy, in a ratio which provides an additive and synergistic effect, and to the combined use of these specific compds. and/or radiotherapy for the manufacture of corresponding pharmaceutical combination prepns. The pharmaceutical combination can include selected protein tyrosine kinase receptor antagonists and further chemotherapeutic or naturally occurring semisynthetic or synthetic agents.

IT 439081-18-2
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(drug combinations for diseases involving cell proliferation and migration or apoptosis or angiogenesis including protein tyrosine kinase receptor antagonists and radiotherapy)

RN 439081-18-2 CAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[[(3S)-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4-(dimethylamino)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



L12 ANSWER 6 OF 7 USPATFULL on STN

ACCESSION NUMBER:	2006:68089 USPATFULL
TITLE:	Combinations for the treatment of diseases involving cell proliferation
INVENTOR(S):	Munzert, Gerd, Ulm, GERMANY, FEDERAL REPUBLIC OF Steegmaier, Martin, Wien, AUSTRIA Baum, Anke, Vienna, AUSTRIA
PATENT ASSIGNEE(S):	Boehringer Ingelheim International GmbH, Ingelheim, GERMANY, FEDERAL REPUBLIC OF (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2006058311	A1	20060316	
APPLICATION INFO.:	US 2005-189540	A1	20050726	(11)

	NUMBER	DATE
PRIORITY INFORMATION:	EP 2004-19361	20040814
	EP 2004-19448	20040817

DOCUMENT TYPE:	Utility
FILE SEGMENT:	APPLICATION
LEGAL REPRESENTATIVE:	MICHAEL P. MORRIS, BOEHRINGER INGELHEIM CORPORATION,

900 RIDGEBURY ROAD, P. O. BOX 368, RIDGEFIELD, CT, 06877-0368, US
NUMBER OF CLAIMS: 24
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 8 Drawing Page(s)
LINE COUNT: 3176
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed are pharmaceutical compositions for the treatment of diseases which involve cell proliferation. Also disclosed are methods for the treatment of said diseases, comprising co-administration of a compound 1 of Formula (I) ##STR1## wherein the groups L, R.sup.1, R.sup.2, R.sup.3, R.sup.4 and R.sup.5 have the meanings given herein and of an effective amount of an active compound 2 and/or co-treatment with radiation therapy, in a ratio which provides an additive and synergistic effect, and to the combined use of a compound 1 of Formula (I) and of an effective amount of an active compound 2 and/or radiotherapy for the manufacture of corresponding pharmaceutical combination preparations.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 439081-18-2
(preparation of aminopteridinones for use in combination therapy for treatment of cell proliferative diseases)
RN 439081-18-2 USPATFULL
CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[[(3S)-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4-(dimethylamino)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



L12 ANSWER 7 OF 7 USPATFULL on STN
ACCESSION NUMBER: 2006:41241 USPATFULL
TITLE: Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
INVENTOR(S): Jung, Birgit, Biberach, GERMANY, FEDERAL REPUBLIC OF
Himmelsbach, Frank, Mittelbiberach, GERMANY, FEDERAL REPUBLIC OF
PATENT ASSIGNEE(S): Boehringer Ingelheim International GmbH, Ingelheim, GERMANY, FEDERAL REPUBLIC OF (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2006035893	A1	20060216	
APPLICATION INFO.:	US 2005-189643	A1	20050726	(11)

	NUMBER	DATE
PRIORITY INFORMATION:	EP 2004-18808	20040807

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: MICHAEL P. MORRIS, BOEHRINGER INGELHEIM CORPORATION, 900 RIDGEBURY ROAD, P. O. BOX 368, RIDGEFIELD, CT, 06877-0368, US
NUMBER OF CLAIMS: 28
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 1 Drawing Page(s)
LINE COUNT: 8735
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to novel pharmaceutical compositions comprising at least one EGFR kinase inhibitor and at least one additional active compound selected from beta-2 mimetics, steroids, PDE-IV inhibitors, p38 MAP kinase inhibitors, NK.sub.1 antagonists and endothelin-antagonists, processes for preparing the compositions and the use thereof as medicament in the treatment of respiratory or gastrointestinal complaints, as well as inflammatory diseases of the joints, the skin or the eyes.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 439081-17-1 439081-18-2
(pharmaceutical compns. for treatment of respiratory and gastrointestinal disorders)

RN 439081-17-1 USPATFULL
CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[[(3R)-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4-(dimethylamino)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 439081-18-2 USPATFULL
CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[[(3S)-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4-(dimethylamino)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



```
=> d his

     (FILE 'HOME' ENTERED AT 10:55:13 ON 13 NOV 2007)

     FILE 'REGISTRY' ENTERED AT 10:55:24 ON 13 NOV 2007
L1             STRUCTURE UPLOADED
L2           6 S L1 FULL

     FILE 'MEDLINE, CAPLUS, WPIDS, USPATFULL' ENTERED AT 10:55:57 ON 13 NOV
     2007
L3          17 S L2
L4           7 S L3 AND CANCER
L5          10 S L3 AND COMBINATION
L6           4 S L5 AND "PHARMACEUTICAL COMBINATION"

     FILE 'REGISTRY' ENTERED AT 11:28:05 ON 13 NOV 2007
               E "4-[(3-CHLORO-4- FLUOROPHENYL)AMINO]-6-{[4-(N,N-DIMETHYLAMINO
               E "4-[(3-CHLORO-4-FLUOROPHENYL)AMINO]-6-{[4-(N,N-DIMETHYLAMINO)
L7             STRUCTURE UPLOADED
L8           6 S L7 FULL

     FILE 'MEDLINE, CAPLUS, WPIDS, USPATFULL' ENTERED AT 11:34:13 ON 13 NOV
     2007
L9          34 S L8
L10          4 S L3 AND L9
L11          9 S L9 AND (CANCER OR TUMOR)
L12          7 S L11 AND COMBINATION

=>

---Logging off of STN---


=>
Executing the logoff script...


=> LOG Y

COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                    84.73     582.08

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                    -6.24     -10.14

STN INTERNATIONAL LOGOFF AT 11:40:48 ON 13 NOV 2007
```